Skip to Content
UW Health SMPH
American Family Children's Hospital
Justine Y. Bruce, MD close
Justine Y. Bruce, MD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Justine Y. Bruce, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Justine Bruce, MD, earned her medical degree at the University of Texas Southwestern Medical School in Dallas and completed her residency at the University of Texas Southwestern Medical School. Dr. Bruce completed a fellowship at the University of Chicago Hospitals and is board certified in internal medicine.


Medical Oncology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hospice and Palliative Medicine
Internal Medicine
Medical Oncology
Fellowship University of Chicago Hospitals, Chicago, IL
Residency University of Texas Southwestern Medical Center, Dallas
Internship University of Texas Southwestern Medical Center, Dallas
Medical School University of Texas Southwestern Medical School, Dallas, TX, 2002

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Programs & Conditions

PubMed Articles
Bruce JY Scully PC Carmichael LL Eickhoff JC Perlman SB Kolesar JM Heideman JL Jeraj R Liu G . Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer Chemother Pharmacol. 2015 Jul;76(1):187-95
[PubMed ID: 26021741]
Hussain M Corn PG Michaelson MD Hammers HJ Alumkal JJ Ryan CJ Bruce JY Moran S Lee SY Lin HM George DJ . Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res. 2014 Aug 15;20(16):4218-27
[PubMed ID: 24965748]
Bruce JY Kolesar JM Hammers H Stein MN Carmichael L Eickhoff J Johnston SA Binger KA Heideman JL Perlman SB Jeraj R Liu G . A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar;73(3):485-93
[PubMed ID: 24414551]
Bruce JY Lang JM McNeel DG Liu G . Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22
[PubMed ID: 23271258]
Bruce JY Eickhoff J Pili R Logan T Carducci M Arnott J Treston A Wilding G Liu G . A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs. 2012 Apr;30(2):794-802
[PubMed ID: 21174224]